Nektar Therapeutics (NKTR) Given New $45.00 Price Target at Mizuho

Nektar Therapeutics (NASDAQ:NKTR) had its target price raised by Mizuho from $30.00 to $45.00 in a research report released on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on the company. J P Morgan Chase & Co reiterated a buy rating and set a $44.00 target price on shares of Nektar Therapeutics in a research report on Monday, November 13th. Canaccord Genuity began coverage on Nektar Therapeutics in a research report on Thursday, November 9th. They set a buy rating and a $35.00 target price for the company. Jefferies Group LLC reiterated a buy rating and set a $35.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, November 8th. Cowen and Company began coverage on Nektar Therapeutics in a research report on Tuesday, November 7th. They set an outperform rating for the company. Finally, ValuEngine upgraded Nektar Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $35.58.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $44.99 on Tuesday. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $46.98.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. The firm had revenue of $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company’s revenue was up 321.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS. analysts predict that Nektar Therapeutics will post -0.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/nektar-therapeutics-nktr-given-new-45-00-price-target-at-mizuho/1783163.html.

In other news, COO John Nicholson sold 15,910 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $37.78, for a total value of $601,079.80. Following the transaction, the chief operating officer now owns 249,066 shares in the company, valued at $9,409,713.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Stephen K. Doberstein sold 396,323 shares of Nektar Therapeutics stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total value of $11,493,367.00. Following the sale, the senior vice president now owns 52,016 shares in the company, valued at $1,508,464. The disclosure for this sale can be found here. Insiders sold 941,427 shares of company stock worth $24,663,626 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the last quarter. LS Investment Advisors LLC grew its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 535 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Nektar Therapeutics in the third quarter valued at $129,000. Mark Sheptoff Financial Planning LLC grew its position in shares of Nektar Therapeutics by 79.4% in the third quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Flinton Capital Management LLC grew its position in Nektar Therapeutics by 75.7% during the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 3,392 shares in the last quarter. 94.97% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with our FREE daily email newsletter.

 


Latest News

MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity


Leave a Reply

 
© 2006-2017 BBNS.